Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...

The U.S. government is putting down $500 million toward the development of a “universal” vaccine—a shot designed to protect ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

The National Institutes of Health (NIH) is planning to freeze the flow of funds to institutions outside of the U.S., ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

With the walls quickly closing in, Kronos Bio has accepted a buyout from notorious biotech acquirer Concentra Biosciences. | With the walls quickly closing in, Kronos Bio has accepted a buyout from ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

The National Institutes of Health (NIH) is following in the FDA’s footsteps—away from animal testing.  | The National ...

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...